A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Key facts
- Where
- Arvada, Houston, Idaho Falls, and Orlando, United StatesSee the 4 sites
- Phase
- Phase 3
Where in United States
- Western Nephrology - ArvadaArvada, United StatesNo longer taking part
- Prolato Clinical Research Center - Kirby DrHouston, United StatesNo longer taking part
- Idaho Kidney Institute- Idaho FallsIdaho Falls, United StatesNo longer taking part
- CTR Oakwater, LLCOrlando, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vertex Pharmaceuticals Incorporated
- Trial code
- NCT07807995EU 2025-525064-14-00
- Record updated
- 19 October 2026
- Original description
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).Read full original descriptionShow less
A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
Inclusion: Completed the Week 104 visit in the parent study VX24-AIS-D08 (NCT06564142) and has not permanently discontinued study drug; Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 15 milliliters per minute (mL/min)/1.73 square meter (m\^2) within 45 days of Day 1 of this study.
Exclusion: Planned participation in another interventional, therapeutic clinical trial (other than the parent study); Other protocol defined Inclusion/Exclusion criteria may apply.